The offering is a routine capital raise for a pre-revenue biotech with positive Phase 3 data. Monitor the timing of the NDA submission and any updates on the XR tablet Phase 3 trial (CHAPTER-3). The modest dilution is offset by extended cash runway, but no near-term catalyst from this filing alone.
Price Chart
Executive Summary
Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share, with an option for an additional 581,199 shares. The offering is expected to raise approximately $107.5 million in net proceeds (or $123.7 million if the option is fully exercised), which will be used to fund late-stage clinical programs, US commercialization efforts, and working capital. The company reported $247 million in cash as of March 31, 2026, and the offering extends its runway into the first half of 2028.
Key Facts
- Offering 3,874,664 shares at $29.68 per share, total gross proceeds of $115 million
- Underwriters have a 30-day option to purchase up to an additional 581,199 shares
- Net proceeds estimated at $107.5 million ($123.7 million with option exercise)
- Proceeds to fund R&D for late-stage programs, US commercialization, and working capital
- Cash and cash equivalents of approximately $247 million as of March 31, 2026
- Immediate dilution of $23.51 per share for new investors based on December 31, 2025 book value
- Shares outstanding will increase from 65,210,590 to up to 69,666,453 (if option exercised)
- Company plans to submit NDA for deucrictibant IR capsules in H1 2026
Financial Impact
Dilution of ~5.9% to existing shareholders; net proceeds of $107.5M extend runway into H1 2028
Risk Factors
- Immediate dilution of $23.51 per share for new investors
- No revenue, pre-commercial stage; reliance on regulatory approval
- Potential further dilution if additional capital is needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-214985 |
| Document: d36127dexfilingfees.htm | 0001193125-26-214985 |
| Document: 0001193125-26-214985-index-headers.html | 0001193125-26-214985 |
| Document: 0001193125-26-214985-index.html | 0001193125-26-214985 |
| Document: 0001193125-26-214985.txt | 0001193125-26-214985 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access